The Avastin® biosimilars market is projected to witness noteworthy growth over the coming years
In 2020, revenues from the sales of Avastin®, Roche’s anti-VEGFA antibody based therapeutic, were observed to have declined by 25% due to competition from biosimilars, in the United States, Europe, Japan, and other nations where it is approved
For additional details, please visit
https://www.rootsanalysis.com/reports/avastin-biosimilars-pipeline-review-and-partnerships.html
In 2020, revenues from the sales of Avastin®, Roche’s anti-VEGFA antibody based therapeutic, were observed to have declined by 25% due to competition from biosimilars, in the United States, Europe, Japan, and other nations where it is approved
For additional details, please visit
https://www.rootsanalysis.com/reports/avastin-biosimilars-pipeline-review-and-partnerships.html
The Avastin® biosimilars market is projected to witness noteworthy growth over the coming years
In 2020, revenues from the sales of Avastin®, Roche’s anti-VEGFA antibody based therapeutic, were observed to have declined by 25% due to competition from biosimilars, in the United States, Europe, Japan, and other nations where it is approved
For additional details, please visit
https://www.rootsanalysis.com/reports/avastin-biosimilars-pipeline-review-and-partnerships.html
0 Comments
0 Shares